Hot Topics Clinical Medicine ACHA Annual Meeting Boston, MA May 31, 2013.

Slides:



Advertisements
Similar presentations
HPV Testing and Genotyping
Advertisements

Cervical Screening Guidelines - for now and the future - Meg McLachlin, MD, FRCPC.
Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University.
MANAGEMENT OF ABNORMAL PAP SMEAR
MANAGEMENT OF THE ABNORMAL PAP SMEAR
How to do cervical pap smear
Updates on Pap Smear Guidelines 2014
Speaker: Decca Mohammed, MD.  Statistics for cervical cancer and HPV  Association of HPV to cervical cancer, and other cancers  Prevention  Screening.
ASHLYN SAVAGE, MD, MSCR ASSOCIATE PROFESSOR OBSTETRICS AND GYNECOLOGY MEDICAL UNIVERSITY OF SOUTH CAROLINA Managing Abnormal Pap Smears: Incorporating.
Sample Taker Training Cervical Cytology & Management of Abnormalities.
Cervical Cancer: Molecular Impact of an Infectious Disease.
Screening for Cervical Cancer
Management of Women with CIN 1 or LSIL
Spotlight on Cervical Cancer Screening
Benign and premalignant disease of the cervix
Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for Screening Obstetrics and Gynecology, Volume 103,
Clinical Uses of HPV DNA Testing
Cervical Cancer Early Detection Can Save Your Life.
Human Papilloma virus testing Research Center for Genetic Engineering and Biotechnology “Georgi D. Efremov”, MASA What is Human Papillomavirus? Human papilloma.
COLPOSCOPY Cervical Screening QARC Training School October 2012.
Educational Module Cervical Cancer Screening.  Estimated new cases: 610  Estimated deaths: 150 Regular Pap tests combined with the HPV vaccine can.
Cervical Cancer Screening
HPV and Cervical Cancer Screening and Prevention.
Screening Tests for Brest & Cervical Cancer
Review of the Guidelines for Cervical Screening in New Zealand Presentation for smear-takers September 2008.
CANCER CERVIX A PREVENTABLE CANCER Dr NEETA DHABHAI Sr Consultant. – Gynaecologist Member Expert - Indian Cancer Winners’ Association
Cervical Cancer in California Janet Bates, MD MPH Research Program Director Research and Surveillance Program California Cancer Registry.
Women’s First Health Center Drs. Sylvester, Youngren, Lo and Sansobrino What You Should Know About Cervical Cancer: Part one in a series of four updates.
Screening for Cervical Cancer Max Brinsmead MB BS PhD May 2015.
Abnormal Pap in Pregnancy Alexander Burnett, MD Division Gyn Oncology, UAMS April, 2006.
SoftPAP® A Novel Collection Device for Cervical Cytology.
Current guidelines for Cervical Cancer Screening
Copyright © 2005, Duke Internal Medicine Residency Curriculum and DHTS Technology Education Services Duke Internal Medicine Residency Curriculum Screening.
In the Name of God. Screening of Cervical Cancer Pap smear and colposcopy F.Behnamfar Gynecology Oncology Fellowship Associate Professor Isfahan University.
International Scientific Congress for Students, Young Physicians and Pharmacists Marisiensis 2014.
CERVICAL/VAGINAL CYTOLOGY
Cervical Intraepithelial Neoplasm
Top Pap smear Questions. 1-When should Pap screening begin? Age 21 y/o,3yrs after first intercourse.
Cases. Case 2 Case 3 Normal cervix - Spatula and brush.
A non-enveloped DNA virus which infects the skin/ mucous membranes of humans.
HPV as Primary Screening for Cervical Cancer: Ready for Prime Time? ACOG Annual Clinical Meeting May 4, 2015.
Cervical Cancer Screening Measure Updates (CMS #124)
Gynecologic Cytopathology
Cervical Cancer Screening Guidelines Update
Cervical Cancer Screening and Sexually Transmitted Infection Case Study PCP version
Screening of genital cancers Evidence Based Presented by Dr\ Heba Nour.
2006 ASCCP Consensus Guidelines Anne L. Kittendorf, MD FAAFP Assistant Professor University of Michigan Department of Family Medicine.
HPV and Pap Guidelines Jennifer Johnson MD. Objectives 1. Define the new PAP guidelines. 2. Identify the historical trends and new evidence resulting.
Will Pap Smears become a thing of the past? J. L. Ellis, M.D.
To pap or not to pap: and what to do when you do Kimberly Swan MD Minimally Invasive Gynecologic Surgery Assistant Professor Ob/Gyn University of Kansas.
HPV AND WOMEN’S CANCER A.C. Evans. M.D., Ph.D.. HPV and Women’s Cancer I have no relevant financial relationships with the manufacturer(s) of any commercial.
Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Cervical Cancer Screening With Both Human Papillomavirus.
HIV Infection Increases Risk of ASCUS and Subsequent Development of SILs Slideset on: Duerr A, Paramsothy P, Jamieson DJ, et al. Effect of HIV infection.
Cytopathology Feb
New Technologies in cervical cancer screening Cosette Wheeler, University of New Mexico Albuquerque, New Mexico.
1 Cervical Cancer Screening Updates Dr. GORDON JOHNSON.
Contact: PRELIMINARY RESULTS OF FIRST HPV PRIMARY SCREENING PRIVATE SECTOR IN BUENOS AIRES FEMALE POPULATION R. Jiménez del Toro,
Cervical Cancer Screening
Public Health England leads the NHS Screening Programmes
Fig. 1. Framework of developing a guideline for cervical cancer screening. ① Benefits of pap test screening, ② harms of pap test screening, ③ accuracy.
Performance of mRNA- and DNA-based high-risk human papillomavirus assays in detection of high-grade cervical lesions ELINA VIRTANEN1, ILKKA KALLIALA2,3,
Cervical Cancer in California
Updates on Pap Smear Guidelines 2014
“Take the Test: Not the Risk” HPV and Cervical Cancer
Detection of TERC Amplification in Cervical Epithelial Cells for the Diagnosis of High- Grade Cervical Lesions and Invasive Cancer  Jing Jiang, Li-Hui.
Public Health England leads the NHS Screening Programmes
SH-sheikhhasani Gyn-oncologist
American Society of Cytopathology’s CELL Talks
Presentation transcript:

Hot Topics Clinical Medicine ACHA Annual Meeting Boston, MA May 31, 2013

Boston University Slideshow Title Goes Here Important publication-LAST  Consensus Guidelines (2012) The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: Background and Consensus Recommendations From the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology  Journal of Lower Genital Tract Disease, July 2012 Hot Topics, Clinical Medicine 2 10/10/2015

Boston University Slideshow Title Goes Here Basic intervals, normal pap history  Don’t start paps until 21  every 3 years, no co-testing  every 3 years or every 5 years with co-testing  Over 65 no testing Hot Topics, Clinical Medicine 3 10/10/2015

Boston University Slideshow Title Goes Here Hot Topics, Clinical Medicine 4 10/10/2015 Unsatisfactory cytology on pap  With liquid-based technology, most reasons for unsatisfactory cytology are eliminated EXCEPT inadequate cells  Don’t use negative HPV co-testing as a reason not to repeat  Repeat test in 2-4 months

Boston University Slideshow Title Goes Here Hot Topics, Clinical Medicine 5 10/10/2015

Boston University Slideshow Title Goes Here Absent EC/TZ  Prior recommendation was early repeat  Under 30, manage as normal  Over 30, co-test or manage as normal  If negative co-test, routine repeat  If positive co-test, repeat cyto+co-test 1 year or  Genotype for 16, 18 Hot Topics, Clinical Medicine 6 10/10/2015

Boston University Slideshow Title Goes Here Hot Topics, Clinical Medicine 7 10/10/2015

Boston University Slideshow Title Goes Here New concept Hot Topics, Clinical Medicine 8 10/10/ , 18?

Boston University Slideshow Title Goes Here  Test Name Result Flag(s) Reference Range Reported Date Footnote  CLINICAL INFORMATION: SEE NOTE  ALL NL PAPS  LMP: 4/6/2013  PREV. PAP: N/A  PREV. BX: N/A  SOURCE: Cervix  STATEMENT OF ADEQUACY: SEE NOTE  Satisfactory for evaluation. Endocervical/transformation zone component present.  INTERPRETATION/RESULT: SEE NOTE  Negative for intraepithelial lesion or malignancy.  INFECTION: SEE NOTE  Shift in vaginal flora suggestive of bacterial vaginosis.  COMMENT: SEE NOTE  This Pap test has been evaluated with computer assisted technology.  CYTOTECHNOLOGIST: SEE NOTE  CXP, CT(ASCP)  HPV DNA (HIGH RISK) DETECTED A (NOT DETECTED)  High-risk HPV types 16,18,31,33,35,39,45,51,52,56,58,59, or 68 may cause cervical cancer or itsprecursors.The analytical performance characteristics of thisassay, when used to test SurePath or vaginal specimens,have been determined by Quest Diagnostics.Methodology: Hybrid Capture with Signal Amplification. Hot Topics, Clinical Medicine 9 10/10/2015

Boston University Slideshow Title Goes Here Hot Topics, Clinical Medicine 10 10/10/2015

Boston University Slideshow Title Goes Here New concept Hot Topics, Clinical Medicine 11 10/10/2015

Boston University Slideshow Title Goes Here Hot Topics, Clinical Medicine 12 10/10/2015

Boston University Slideshow Title Goes Here Hot Topics, Clinical Medicine 13 10/10/2015

Boston University Slideshow Title Goes Here Hot Topics, Clinical Medicine 14 10/10/2015